Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted ...
The company granted stock options to purchase an aggregate of 208,350 shares of Nurix common stock and restricted stock unit ...
In a pioneering collaboration with AbbVie, Northwestern researchers have discovered a new way to potentially treat cancer by ...
High levels of fat mass and obesity-associated protein (FTO) have been linked to increased tumor growth and resistance to ...
Merck Sharp & Dohme LLC patents report the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase (Von Hippel-Lindau disease tumor suppressor [VHL] ligands) ...
High levels of fat mass and obesity-associated protein (FTO) have been linked to increased tumor growth and resistance to ...
Herbicide development has slowed in recent years, but innovative research methods could soon drive significant progress in ...
Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to an androgen receptor targeting moiety through a linker acting as androgen ...
11d
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...
When encountering cellular stress, E3 ligases must deal with proteins that have been damaged in many different ways. For example, misfolding can expose multiple hydrophobic regions in the same ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback